540 related articles for article (PubMed ID: 25466631)
1. Hemophagocytic lymphohistiocytosis (HLH): A heterogeneous spectrum of cytokine-driven immune disorders.
Brisse E; Wouters CH; Matthys P
Cytokine Growth Factor Rev; 2015 Jun; 26(3):263-80. PubMed ID: 25466631
[TBL] [Abstract][Full Text] [Related]
2. Mouse Cytomegalovirus Infection in BALB/c Mice Resembles Virus-Associated Secondary Hemophagocytic Lymphohistiocytosis and Shows a Pathogenesis Distinct from Primary Hemophagocytic Lymphohistiocytosis.
Brisse E; Imbrechts M; Put K; Avau A; Mitera T; Berghmans N; Rutgeerts O; Waer M; Ninivaggi M; Kelchtermans H; Boon L; Snoeck R; Wouters CH; Andrei G; Matthys P
J Immunol; 2016 Apr; 196(7):3124-34. PubMed ID: 26903481
[TBL] [Abstract][Full Text] [Related]
3. Hemophagocytic lymphohistiocytosis: a review inspired by the COVID-19 pandemic.
Soy M; Atagündüz P; Atagündüz I; Sucak GT
Rheumatol Int; 2021 Jan; 41(1):7-18. PubMed ID: 32588191
[TBL] [Abstract][Full Text] [Related]
4. [Heterogeneity of HLH pathophysiology and treatment strategies].
Yasumi T; Shibata H; Shimodera S; Heike T
Rinsho Ketsueki; 2015 Oct; 56(10):2248-57. PubMed ID: 26458466
[TBL] [Abstract][Full Text] [Related]
5. Advances in the pathogenesis of primary and secondary haemophagocytic lymphohistiocytosis: differences and similarities.
Brisse E; Wouters CH; Matthys P
Br J Haematol; 2016 Jul; 174(2):203-17. PubMed ID: 27264204
[TBL] [Abstract][Full Text] [Related]
6. Lytic viral replication and immunopathology in a cytomegalovirus-induced mouse model of secondary hemophagocytic lymphohistiocytosis.
Brisse E; Imbrechts M; Mitera T; Vandenhaute J; Wouters CH; Snoeck R; Andrei G; Matthys P
Virol J; 2017 Dec; 14(1):240. PubMed ID: 29258535
[TBL] [Abstract][Full Text] [Related]
7. Hemophagocytic lymphohistiocytosis: Pathogenesis, diagnosis, and management.
Morimoto A; Nakazawa Y; Ishii E
Pediatr Int; 2016 Sep; 58(9):817-25. PubMed ID: 27289085
[TBL] [Abstract][Full Text] [Related]
8. Hemophagocytic syndrome: primary forms and predisposing conditions.
Sepulveda FE; de Saint Basile G
Curr Opin Immunol; 2017 Dec; 49():20-26. PubMed ID: 28866302
[TBL] [Abstract][Full Text] [Related]
9. Treatment of hemophagocytic lymphohistiocytosis with alemtuzumab in systemic lupus erythematosus.
Keith MP; Pitchford C; Bernstein WB
J Clin Rheumatol; 2012 Apr; 18(3):134-7. PubMed ID: 22426581
[TBL] [Abstract][Full Text] [Related]
10. Janus kinase inhibition lessens inflammation and ameliorates disease in murine models of hemophagocytic lymphohistiocytosis.
Das R; Guan P; Sprague L; Verbist K; Tedrick P; An QA; Cheng C; Kurachi M; Levine R; Wherry EJ; Canna SW; Behrens EM; Nichols KE
Blood; 2016 Mar; 127(13):1666-75. PubMed ID: 26825707
[TBL] [Abstract][Full Text] [Related]
11. Pathogenesis of Hemophagocytic Lymphohistiocytosis.
Filipovich AH; Chandrakasan S
Hematol Oncol Clin North Am; 2015 Oct; 29(5):895-902. PubMed ID: 26461149
[TBL] [Abstract][Full Text] [Related]
12. COVID-19-associated cytokine storm syndrome and diagnostic principles: an old and new Issue.
Yongzhi X
Emerg Microbes Infect; 2021 Dec; 10(1):266-276. PubMed ID: 33522893
[TBL] [Abstract][Full Text] [Related]
13. Familial and acquired hemophagocytic lymphohistiocytosis.
Janka G; zur Stadt U
Hematology Am Soc Hematol Educ Program; 2005; ():82-8. PubMed ID: 16304363
[TBL] [Abstract][Full Text] [Related]
14. Hemophagocytic lymphohistiocytosis: when the immune system runs amok.
Janka G
Klin Padiatr; 2009 Sep; 221(5):278-85. PubMed ID: 19707989
[TBL] [Abstract][Full Text] [Related]
15. Rapamycin does not control hemophagocytic lymphohistiocytosis in LCMV-infected perforin-deficient mice.
Rothman JA; Das R; Teachey DT; Paessler ME; Nichols KE
Pediatr Blood Cancer; 2011 Dec; 57(7):1239-43. PubMed ID: 21681935
[TBL] [Abstract][Full Text] [Related]
16. Cell Versus Cytokine - Directed Therapies for Hemophagocytic Lymphohistiocytosis (HLH) in Inborn Errors of Immunity.
Wegehaupt O; Wustrau K; Lehmberg K; Ehl S
Front Immunol; 2020; 11():808. PubMed ID: 32457750
[TBL] [Abstract][Full Text] [Related]
17. Ruxolitinib-loaded cytokine nanosponge alleviated the cytokine storm and dampened macrophage overactivation for the treatment of hemophagocytic lymphohistiocytosis.
Wang H; Wang Y; Liu H; Li X; Sun C; Pang Z; Zhang B; Hu Y
Int J Pharm; 2024 May; 657():124127. PubMed ID: 38621611
[TBL] [Abstract][Full Text] [Related]
18. [Hemophagocytic Lymphohistiocytosis].
Stalder G; Ribi C; Duchosal MA
Praxis (Bern 1994); 2018 Aug; 107(16):902-911. PubMed ID: 30086687
[TBL] [Abstract][Full Text] [Related]
19. Hemophagocytic syndromes--an update.
Janka GE; Lehmberg K
Blood Rev; 2014 Jul; 28(4):135-42. PubMed ID: 24792320
[TBL] [Abstract][Full Text] [Related]
20. Cytokine storm and targeted therapy in hemophagocytic lymphohistiocytosis.
Zhang HQ; Yang SW; Fu YC; Chen MC; Yang CH; Yang MH; Liu XD; He QN; Jiang H; Zhao MY
Immunol Res; 2022 Oct; 70(5):566-577. PubMed ID: 35819695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
